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Abstract
Rationale: Cancer stem cells (CSCs) have been implicated as the seeds of therapeutic resistance and
metastasis, due to their unique abilities of self-renew, wide differentiation potentials and resistance to most
conventional therapies. It is a proactive strategy for cancer therapy to eradicate CSCs. Methods: Tumor
tissue-derived breast CSCs (BCSC), including XM322 and XM607, were isolated by fluorescence-activated
cell sorting (FACS); while cell line-derived BCSC, including MDA-MB-231.SC and MCF-7.SC, were purified by
magnetic-activated cell sorting (MACS). Analyses of microRNA and mRNA expression array profiles were
performed in multiple breast cell lines. The mentioned nanoparticles were constructed following the standard
molecular cloning protocol. Tissue microarray analysis has been used to study 217 cases of clinical breast
cancer specimens. Results: Here, we have successfully established four long-term maintenance BCSC that
retain their tumor-initiating biological properties. Our analyses of microarray and qRT-PCR explored that
miR-34a is the most pronounced microRNA for investigation of BCSC. We establish hTERT promoter-driven
VISA delivery of miR-34a (TV-miR-34a) plasmid that can induce high throughput of miR-34a expression in
BCSC. TV-miR-34a significantly inhibited the tumor-initiating properties of long-term-cultured BCSC in vitro
and reduced the proliferation of BCSC in vivo by an efficient and safe way. TV-miR-34a synergizes with
docetaxel, a standard therapy for invasive breast cancer, to act as a BCSC inhibitor. Further mechanistic
investigation indicates that TV-miR-34a directly prevents C22ORF28 accumulation, which abrogates
clonogenicity and tumor growth and correlates with low miR-34 and high C22ORF28 levels in breast cancer
patients. Conclusion: Taken together, we generated four long-term maintenance BCSC derived from either
clinical specimens or cell lines, which would be greatly beneficial to the research progress in breast cancer
patients. We further developed the non-viral TV-miR-34a plasmid, which has a great potential to be applied as
a clinical application for breast cancer therapy.
Key words: cancer stem cells; breast cancer; targeted drug delivery; miR-34a; C22ORF28; therapeutic target.

Introduction
Cancer stem cells (CSCs), also known as
tumor-initiating cells, have been implicated as the
seeds of metastasis and sources of therapy resistance,
due to their unique abilities of self-renew, wide

differentiation potentials and resistance to most
conventional therapies. It is an attractive therapy
strategy for treating cancer to eradicate CSCs [1, 2].
However, long-term-cultured CSC lines are rarely
http://www.thno.org
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generated in most investigations, and the reported
treatment effects and mechanisms within CSCs have
been intensively questioned. It is difficult to make a
distinction between therapeutic response and
self-differentiation of CSCs. With a goal of unlocking
this mystery, we isolated, identified and maintained
tumor tissue-derived breast CSCs (BCSC) in our
recent reported investigation [3]. In sum, prolonged
maintenance of CSCs could be a great benefit for
enabling research progress in patients with tumors.
The tumor-initiating properties of CSCs
distinguish them from the remainder of cancer cells,
and play a key role in therapeutic resistance, evasion
of cell death, as well as dormancy [4]. Therefore, it
remains an effective approach to eradicate CSCs
through regulating determinants of tumor-initiating
properties. On the other hand, it is well known that
microRNAs, a class of small non-coding RNAs, can
post-transcriptionally mediate gene expression of
neoplasm. Multiple researches indicated that
microRNAs could efficiently induce pluripotent stem
cells to generate cell lineage without stemness
characteristics, mediate self-renewal of stem cells and
even determine their cell fate [5-7]. Consequently,
microRNA interference might potentially be
implicated in the tumor-initiating properties and cell
fate of long-term-cultured CSCs.
Since conventional therapy is not effective
against CSCs, novel therapeutic strategies applying
nanoparticle systems to deliver target-specific
molecules have become promising approaches for
potentially eliminating them [8-10]. Nanomedicine, as
one of the fastest growing applications of
nanotechnology, presents several outstanding
advantages over conventional chemotherapeutics:
enhanced permeability and retention effect, better
surface modification for active tumor targeting,
tunability of drug release, as well as nano-carriers
with various drug molecules and imaging agents [11].
Although both viral vectors and non-viral vectors are
used for systemic delivery in clinical trials, non-viral
vectors hold the superior advantages of large-scale
production, high level of transduction efficiencies,
low immunogenicity and well-tolerated toxicity in
comparison with viral vectors [8]. Currently, growing
evidences have shown that lipid nanoparticle
technology would be a dominant non-viral
technology to enable the enormous potential of gene
therapy [12].
In our previous researches, we developed
VP16-GAL4-WPRE integrated systemic amplifier
(VISA) as a non-viral targeting vector [13]. This
versatile non-viral VISA vector was successfully
shown to selectively amplify the transcriptional
activity of promoters, with virtually no toxicity in
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pancreatic tumors [13], lung cancer [14], ovarian
cancer [15], hepatocellular carcinoma [16, 17], prostate
cancer [18] and breast cancer [19-22]. Furthermore, we
established the hTERT-promoter-based VISA vector
that drives transgene expression in treating breast
cancer [18, 20, 21]. Our group also found that
VISA-enabled systemic delivery of BikDD reduces the
population of short-term-isolated breast cancer
initiating
cells
[19,
23].
Collectively,
our
above-mentioned investigations urge us to explore
the therapeutic response of long-term-cultured BCSC
to hTERT-promoter-based VISA vector.
In the present study, we tried to exploit a feasible
treatment for long-term-cultured BCSC based on our
previous investigations. Preliminarily, we explored
the most prominent microRNA for investigation in
tumor
tissue-derived
or
cell
line-derived
long-term-cultured BCSC. We further sought to
determine
the
therapeutic
effect
of
hTERT-promoter-based VISA delivery of the specific
microRNA on prolonged maintained BCSC. In
addition, we provided mechanistic insight into this
therapeutic strategy and the tolerability of this
non-viral liposomal nanoparticle.

Methods
Patients and animal study
Informed consent was obtained from all patients.
Studies involved in animal experiments and human
breast cancer tumor collection were approved by the
research ethics committee of Sun Yat-sen University
Cancer Center (SYSUCC).

Isolation and passage of long-term-cultured
BCSC
Tumor tissue-derived BCSC (XM322 and XM607)
were isolated by fluorescence-activated cell sorting
(FACS) as previously described [3]. Cell line-derived
BCSC (MDA-MB-231.SC and MCF-7.SC) were
purified by magnetic-activated cell sorting (MACS).
The application of culture medium was as described
previously [3]. Further details are available in
Supplementary methods.

Patients, tissues, tissue microarray
construction (TMA) and
immunohistochemistry (IHC)
A total of 134 female patients who were
hospitalized in SYSUCC from 2001 to 2006 were
enrolled in our study. Four fresh tissue samples of
breast tumors collected during eradicative operations
performed at Sun Yat-Sen University Cancer Center in
July 2015 were randomly chosen for the Western blot
study. See Supplementary methods for details on data
processing.
http://www.thno.org

Theranostics 2017, Vol. 7, Issue 19
Constructs and transfection
Detailed information of the VISA plasmid,
hTERT promoter-driven VISA nanoparticle delivery
of miR-34a (TV-miR-34a) and hTERT promoter-driven
VISA nanoparticle delivery of control (TV-miR-Ctrl)
were described previously [13, 22]. In brief, the
miR-34a shRNA was incorporated into the Bgl II/Nhe
I sites of the plasmid pGL3-T-VISA-Luc; following,
the T-VISA-miR-34a fragment of pGL3-T-VISA-miR34a was subcloned into the Not I and Sal I sites of
pUK21. Transient transfections were performed as
previously described [22]. Briefly, BCSC were
transiently transfected with 1µg of the hTERT-VISA
plasmid DNA using extruded DOTAP: cholesterol
liposomes in 24-well plates (N/P ratio of 2:1).
C22ORF28-Ad (addition of C22ORF28) and
C22ORF28-KD (knockdown of C22ORF28) were
generated as previously described [24, 25]. For
site-specific mutagenesis, we mutated the regions in
the
C22ORF28-3'UTR
and
LIN28A-3'UTR
complementary to the seed sequence of miR-34a using
the QuikChange II Site-Directed Mutagenesis Kit.
Further details are available in Supplementary methods.

Flow cytometry
Fluorescence-activated cell sorting (FACS) was
performed to analyze the CD44+CD24- subpopulation,
proportion of Lin and population of ALDH1 in BCSC
using antibodies of CD44+, CD24-, Lin-PE and
ALDH1-PE. Details are available in Supplementary
methods.

RNA isolation and real-time PCR
The procedure for miR-34a expression was
described previously [22]. Briefly, total RNA was
extracted from BCSC using TRIzol Reagent
(Invitrogen), according to the manufacturer’s
instructions. The amount of mRNA was determined
relative to 5S ribosomal RNA. Each sample was
analyzed in triplicate.

Serial passages of luciferase-labeled and green
fluorescent protein (GFP)-labeled BCSC
lineages
Establishment
protocols
were
described
previously [3, 13]. Further details are available in
Supplementary methods.

Western blot analysis
Protein extracts of BCSC (10 µg protein) were
separated
using
10%
SDS-PAGE,
and
electrophoretically transferred to polyvinylidene
difluoride (PVDF) membranes. Next, antibodies were
assayed. We purchased primary antibodies of hTERT,
C22ORF28, LIN28A and CD44 from Sigma-Aldrich
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Co. St Louis, USA. GAPDH was designed as a protein
loading control.

Telomerase activity assay
Quantitative Telomerase Detection Kit (Allied
Biotech, Vallejo, CA) was used to evaluate the
telomerase activity in 1 µg of corresponding cell lysate
according to the manufacturer’s instructions.

MTT assay of cell viability
MTT (Sigma) assay was used to assess cell
viability according to the manufacturer’s instructions.
Each assay was repeated five times. Further details
are available in Supplementary methods.

Clonal pair-cell analysis
In brief, BCSC (5×106 cells) were transduced with
GFP-labeled C22ORF28-KD plasmid for 48 h, stained
with 2 µL DAPI (10 µg/mL) for 5 min, and
counterstained with anti-CD44-PE (1:200) for 30 min,
respectively. Preliminarily, GFP-labeled BCSC were
purified and collected. Next, images were acquired by
an inverted epifluorescence microscope system and
further analyzed by digital confocal microscopy.

Clonogenicity assay in soft agarose
Clonogenicity assay in soft agarose was
performed to determine clonal expansion ability of
BCSC as previously described [3]. Further details are
available in Supplementary methods.

Tumor transplantation experiment
To determine the optimum antitumor dose of
T-VISA-miR-34a plasmid in vivo, a suspension of
luciferase-labeled BCSC (1×104 cells) was inoculated
at the left fourth inguinal mammary gland of female
BALB/c-nude mice (6-week-old; Vital River
Laboratories Animal, Beijing, China). Each group
of mice received 100 µL of DNA-liposome complexes
that contained 5 µg TV-miR-34a, 10 µg TV-miR-34a, 20
µg TV-miR-34a, or liposomal complexes administered
via tail vein injection, every other day / quaque omni
die (qod) for 4 consecutive weeks. Moreover, to
investigate the antitumor effect of TV-miR-34a in vivo,
luciferase-labeled BCSC (1×104 cells) were injected
into the left fourth inguinal mammary gland of mice.
When the tumors reached ~50 mm3, the mice were
noninvasively imaged using the IVIS system to
confirm tumor growth and then randomly assigned to
one of three following treatment groups (10 mice per
group): Each group of mice received 100 µL of
DNA-liposome
complexes
that
contained
TV-miR-Ctrl liposomal complexes (10 μg qod),
TV-miR-34a liposomal complexes (10 μg qod) or
liposomal (Ctrl) alone. The secretion levels of serum
alanine transaminase (ALT), aspartate transaminase
http://www.thno.org
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(AST), blood urea nitrogen (BUN) and creatinine (Cr)
were determined with an automatic analyzer (Roche
Cobas Mira Plus; Roche, Mannheim, Germany). The
secretion concentrations of cytokines (TNF-α, IL-6 and
IFN-γ) in mouse sera were quantified using the
cytometric bead array kit for mouse inflammatory
cytokines (CBA; BD Biosciences). The test was
repeated more than five times. See also in
Supplementary methods.

Microarray analysis
RNA was tested by capillary electrophoresis on
an Agilent 2100 bioanalyzer and high quality of
samples was confirmed. Acquired images and the
signal intensities of microRNA spots were evaluated
by GeneSpring GX (Agilent Technologies, Capital
Biochip Corporation) and normalized based on global
signal intensity according to the manufacturer’s
protocol. The results had been submitted to
ArrayExpress (accession number E-MTAB-5584). The
involved gene expressions of BCSC were described
previously (accession number E-MTAB-5057) [3].
Further details are available in Supplementary methods.

Statistical analysis
All values are presented as the mean ± standard
deviation (SD). For comparisons, Student’s t test
(two-tailed), Wilcoxon signed-rank test, Pearson
chi-square test, Pearson correlation analysis, Log-rank
test, Fisher’s exact test, and nonparametric
Mann-Whitney U test were performed as indicated.
Survival rates were analyzed by log-rank test using
SSPS 13.0 software. The significance level was set at p
< 0.05. All data in our study have been recorded at
Sun Yat-sen University Cancer Center for future
reference (number RDDB2017000168).

Results
Identification of in vitro long-term-cultured
BCSC
In our previous work, we successfully generated
and characterized two BCSC lines (BCSC1/XM322,
Figure 1A left panel; and BCSC2/XM607, Figure 1A
right panel) derived from 2 (out of 22) clinical
specimens with surgically resected breast cancer. Both
BCSC lineages showed prolonged maintenance over
20 serial passages in vitro, while their tumor-initiating
biological properties were retained [3]. To better
investigate the innate features of BCSC, we further
generated and maintained two BCSC lineages derived
from breast cancer cell lines: MDA-MB-231.SC and
MCF-7.SC. Here, we performed a magnetic-activated
cell sorting (MACS) method to isolate cell line-derived
BCSC, rather than using a fluorescence-activated cell
sorting (FACS) approach for tumor tissue-derived
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BCSC. Both MDA-MB-231.SC and MCF-7.SC were
isolated successfully and subsequently maintained on
the first try. In a general sense, the success rate of cell
line-derived BCSC isolated by MACS (2/2) is superior
to that of tumor tissue-derived BCSC isolated by
FACS (2/22) without removal of potential
confounding factors (p < 0.05). Two cell line-derived
BCSC sustained more than 20 passages for more than
3 years. Both of the 20th serial passages of BCSC also
held the properties of mammosphere, self-renewal
(MDA-MB-231.SC, Figure 1B left panel; and
MCF-7.SC, Figure 1B right panel), CD44+ CD24-/low
(MDA-MB-231.SC, Supplementary figure S1A left
panel; and MCF-7.SC, Supplementary figure S1A
right panel), Lin- (Supplementary figure S1B) ALDH1+
(Supplementary figure S1C), and clonogenicity in soft
agarose (Supplementary figure S1D). Consistent to the
tumor tissue-derived BCSC we described in a
previous study [3], as few as 1×103 BCSC were
sufficient to enable formation into tumors
(Supplementary figure S1E), while as many as 1×105
breast cancer cells failed to generate tumors within
two months according to the results of tumor
transplantation experiment (Supplementary table S1).
In sum, we successfully generated and maintained
four long-term-cultured BCSC lineages.

Microarray analyses of microRNA expression
profiles to explore the most prominent
microRNA expression in BCSC
Since the hTERT-promoter-based VISA vector
drives transgene expression in multiple tumors, we
aimed to develop the hTERT-promoter-based VISA
delivery of specific microRNA in order to treat
malignant breast cancer cells (breast cancer cells and
BCSC). First of all, we sought the lowest microRNA
expressions in malignant breast cancer cells in
comparison with healthy mammary epithelial cells
(HME). By screening a genome-wide microRNA
array, we explored significant differences of
microRNA expressions among breast cancer cells (BC,
including MDA-MB-231, MCF-7, MDA-MB-468 and
SK-BR-3),
BCSC
(including
MDA-MB-231.SC,
MCF-7.SC, XM322 and XM607), and immortal HME
(184A1 and MCF-12A) (Figure 1C and Supplementary
table S2). We found that miR-34a is the most
pronounced microRNA in microarray analyses. We
further performed quantitative RT-PCR analysis to
confirm these results. Compared with these two
immortalized healthy mammary epithelial cell lines,
miR-34a expression is significantly down-regulated in
both groups of BCs and BCSC (Figure 1D).
Additionally, miR-34a expression had no significant
difference between groups of BCs and BCSC (Figure
1D). To evaluate miR-34a expression in clinical
http://www.thno.org
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specimens,
we
retrospectively
analyzed
clinicopathological data of 134 patients from previous
reports (Supplementary table S3) [3]. Quantitative
RT-PCR analyses indicated that the expression level
of miR-34a in the stage I-II group is lower than that in
their adjacent healthy breast tissue specimens (HBT),
and miR-34a expression within the stage III group
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was lowest among the three mentioned groups
(Figure 1E). So, miR-34a is downregulated in human
breast cancer cells and BCSC in comparison with
healthy breast cells. Therefore, miR-34a is the most
prominent microRNA for further investigation in
long-term-cultured BCSC.

Figure 1. miR-34a is the most pronounced microRNA for further research in long-term-cultured BCSC. (A) Capacities of self-renewal and sphere-formation of
XM322 (left panel) and XM607 (right panel). Scale bar, 100 µm. (B) Capacities of self-renewal and sphere-formation of MDA-MB-231.SC (left panel) and MCF-7.SC (right panel).
Scale bar, 100 µm. (C) Heatmap presents microRNA expressions among immortalized healthy mammary epithelial cells (HME, 184A1 and MCF-12A), breast cancer cells (BC,
contained MDA-MB-231, MCF-7, MDA-MB-468 and SK-BR-3), and BCSC (contained MDA-MB-231.SC, MCF-7.SC, XM322 and XM607). (D) qRT-PCR analysis indicated that
miR-34a expression of HME is significantly higher than that of BC and BCSC. miR-34a expression was normalized to the endogenous control 5S rRNA. NS: not significant. (E)
qRT-PCR analyses indicated that samples within the stage I-II group had significantly lower miR-34a expression compared with those in groups of the adjacent healthy breast
tissue specimens (HBT); additionally, miR-34a expression within stage III patients was lowest among the three groups. ***p<0.001.

http://www.thno.org
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Figure 2. Schematic illustration of TV-miR-34a (targeted expression of micro-RNA-34a by hTERT promoter-driven VISA) plasmid. (A)
Schematic diagram; (B) Schematic structure.

hTERT promoter-driven VISA delivery of
miR-34a (TV-miR-34a) induces high
throughput of miR-34a expression in BCSC
In our previous reports, our group had
established TV-miR-34a plasmid (Figure 2A) and
found that TV-miR-34a can lead to high throughput of
miR-34a in breast cancer cells. To elucidate the
correlations among gene sequences, secondary
structure and function, we precisely analyzed the
gene sequences (Supplementary table S4) and
schematic structure (Figure 2B) of TV-miR-34a
(6973bp). Here we compared the expressions of
human telomerase reverse transcriptase (hTERT)
among the HME, BC and BCSC. Expressions of
hTERT were rarely detectable in both HME cells;
nevertheless, hTERT expressions were high in all BC
and BCSC (Figure 3A). Similarly, telomerase activities

in HME cells were significantly lower than that in
either BCs or BCSC (Figure 3B). Telomerase activity
within group of BCSC seemed to be higher than that
of BCs; however, this association was only on the
borderline (Figure 3B). Given the nature of metabolic
inertness within BCSC, the transfection efficiency of
TV-miR-34a nanoparticle in BCSC remains to be fully
investigated. Therefore, determination of miR-34a
expression within BCSC following TV-miR-34a
transduction is very crucial for this therapeutic
strategy. Since transfection efficiency depends on cell
proliferation,
transduction
rates
and
other
complicated factors [26], we aimed to select out
transfected cells for further investigation. Initially, we
established
plasmids
of
GFP-labeled
Ctrl,
TV-miR-Ctrl and TV-miR-34a. Then, BCSC were
transfected with the above-mentioned plasmids for 48
h, respectively. Next, GFP-positive cells (both single
http://www.thno.org
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cell and pair cells) were purified by FACS (Figure 3C,
representative images of XM322). Finally, telomerase
activities among the HME, BC and BCSC had not been
altered significantly after the corresponding
transfection with Ctrl, TV-miR-Ctrl or TV-miR-34a,
respectively (Figure 3D). In addition, miR-34a
expressions in purified GFP-labeled BCSC were
determined by quantitative RT-PCR. The normalized
value of miR-34a/5s rRNA in TV-miR-34a-infected
BCSC significantly increased from 206.56 ± 27.53 (n=3)
to 255.59 ± 86.97 (n=3), while the miR-34a relative
value in TV-miR-34a-infected BCs enhanced
significantly from 322.87 ± 137.59 (n=3) to 405.77 ±
162.17 (n=3) (Figure 3E). Here we found that there
was no significant difference between BCs and BCSC
following TV-miR-34a treatment (Figure 3E). In
addition, cell viabilities were significantly depressed
by
TV-miR-34a
treatment
in
both
BCSC
(MDA-MB-468, SK-BR-3, MDA-MB-231, MCF-7,
parental cells of XM322 and XM607) and BCs
(MDA-MB-231.SC, MCF-7.SC, XM322 and XM607)
(Figure 3F). Meanwhile, this decrease was more
pronounced in BCSC than in parental breast cancer
cells, as depicted in Figure 3F. In sum, TV-miR-34a
induces high throughput of miR-34a expression in
BCSC, as well as preliminarily eradicates BCSC.

TV-miR-34a significantly inhibits
tumor-initiating properties of
long-term-cultured BCSC in vitro
In the beginning, we explored whether
TV-miR-34a mediates the biological properties of
BCSC. First, we transduced BCSC mammosphere
with TV-miR-34a plasmid. We found that
mammosphere of XM607 initiated to adherence and
differentiation on day 3 (Figure 4A). Next, we found
that TV-miR-34a reduced the proportion of
CD44+CD24-, and this trend was more robust and
persistent in comparison with Ctrl, miR-Ctrl,
TV-miR-Ctrl or miR-34a in XM607; whereas the
influence of miR-34a was transient and reversible
(Figure 4B). Similar results were observed in
MCF-7.SC (Supplementary figure S2). These findings
were exciting because they implied that TV-miR-34a
leads to the inhibition of tumor-initiating properties in
BCSC. Consistent with the above results, we also
found that TV-miR-34a decreased the clonogenicity
ability of MCF-7.SC within soft agarose (Figure 4C).

TV-miR-34a reduces proliferation of BCSC
effectively and safely in vivo
In our previous study, our group found that
TV-miR-34a drastically eliminated breast cancer cells
in vivo [22]. Here, we further investigated whether
TV-miR-34a treatment plays a role in inhibiting BCSC
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proliferation. To confirm the therapeutic response of
TV-miR-34a treatment in vivo, we initially established
and maintained BCSC lineages expressing firefly
luciferase. We found that TV-miR-34a inhibited the
growth of BCSC-bearing tumors in mice by a
dose-dependent manner. With the goal of achieving
most efficacious antitumor activity with lowest
potential toxicity, we selected an optimum dose (10 µg
qod) for TV-miR-34a treatment in XM322-bearing
mouse tumors (Figure 5A). Importantly, luciferase
imaging revealed that treatment with TV-miR-34a led
to significantly decreased bioluminescent signal from
the tumors by day 10 after the first injection (Figure
5B). Additionally, TV-miR-34a prolonged mouse
survival even more effectively than either Ctrl or
TV-miR-Ctrl (Figure 5C).
Besides the efficacy of TV-miR-34a treatment, we
also paid attention on its safety. Inconsistent to our
previous work, [3] we found that body weights for all
participating MDA-MB-231.SC-bearing nude mice did
not change significantly (Figure 5D); suggesting that
the dosage of 10 µg qod is better tolerated than 15 µg
biw for TV-miR-34a, based on the treatment’s
influence on body metabolism. In addition, liver
injury in BALB/c-nude mice was assessed by
measuring the levels of key liver enzymes in the
serum. TV-miR-34a treatment did not affect serum
alanine aminotransferase (ALT) (Figure 5E, left panel)
and aspartate aminotransferase (AST) (Figure 5E,
right panel) in MDA-MB-231.SC-bearing mice.
Similarly, the effect of TV-miR-34a treatment on renal
function of mice was further evaluated in
MDA-MB-231.SC-bearing mice. We found no
difference in levels of both blood urea nitrogen (BUN)
(Figure 5F, left panel) or creatinine (Cr) (Figure 5F,
right panel) among Ctrl, TV-miR-Ctrl and
TV-miR-34a. All these parameters confirmed
BCSC-bearing mice with TV-miR-34a treatment were
physiologically healthy.
The potential immunotoxicities of nanomaterials
have received substantial attention. It is generally
agreed that secretion amounts of proinflammatory
cytokines can be useful tools in evaluating
nanomaterial immunotoxicity [27]. In this study, we
measured the serum proinflammatory cytokines
(TNF-α, IL-6 and IFN-γ) to evaluate immunotoxicity
produced by TV-imR-34a treatment in vivo. The
differences in cytokine concentrations (TNF-α, IL-6
and IFN-γ) between the groups of Ctrl-treated and
TV-miR-Ctrl-treated mice were not statistically
significant (Figure 5G). In comparison with groups of
Ctrl and TV-miR-Ctrl, concentrations of TNF-α, IL-6
and IFN-γ of mice in the study group of TV-miR-34a
treatment were significantly increased from day 0
to day 10 (Figure 5G). Remarkably, 10 days after
http://www.thno.org
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injection of empty vector (liposome 100 µL) in mice,
TNF-α was increased by 3.5-fold, relative to day 0 (p <
0.001). The level of IL-6 was increased by ~3.0-fold
relative to day 0 (p < 0.001). Similarly, the secretion
amount of IFN-γ was increased by 5.7-fold as
compared with day 0 (p < 0.001). Liposome injection
increased immunomodulatory activities in mice in
vivo, suggesting that there remains much space to
develop the versatile empty vector. Although the
mouse immune system was found to release
significantly higher levels of proinflammatory
cytokines (TNF-α, IL-6 and IFN-γ), we did not observe
lethal inflammatory responses in mice throughout
these tests. Therefore, treatment of TV-miR-34a for
BCSC is well-tolerated in vivo.

C22ORF28 (chromosome 22 open reading
frame 28) acts as a direct and functional target
of TV-miR-34a treatment in
long-term-cultured BCSC
Although multiple molecules have been
reported to be direct targets of miR-34a in stem cells
[5, 28], the precise molecular mechanisms of
long-term-cultured BCSC repressed by TV-miR-34a
remain to be established. In our recent research, we
found that POMC, AKT2 and GSK3β could regulate
the tumor-initiating properties of long-term-cultured
BCSC [3]. Next, we speculated whether these
molecules and their related signaling pathways are
involved in the treatment mechanism of TV-miR-34a
on BCSC. First, we used miRWalk 2.0
(http://zmf.umm.uniheidelberg.de/apps/zmf/mirw
alk2) to predict RNA-binding proteins related to
genes of AKT2, GSK3β and POMC (Supplementary
table S5). C22ORF28-3'-UTR (Figure 6A) and
LIN28A3'-UTR (Supplementary figure S3A) were
determined to contain miR-34a-conserved binding
sites. Second, we constructed a luciferase reporter
vector comprising the 3'-UTR or 3'-UTR with
mutation sites of C22ORF28 (Figure 6A) and LIN28A
(Supplementary
figure
S3A).
Encouragingly,
TV-miR-34a
significantly
repressed
luciferase
expressions of Luc-C22ORF28-3'UTR rather than
Luc-LIN28A-3'UTR; whereas the mutation of five
nucleotides at the miR-34a-binding site of
C22ORF28-3'UTR led to complete abrogation of the
suppressive effect (Figure 6B and Supplementary
figure S3B). In order to determine which molecule is
acting as the functional target of TV-miR-34a in
long-term-cultured BCSC, we performed Western
blotting to measure expressions of C22ORF28,
LIN28A and CD44. LIN28A expression was rarely
detectable in all four BCSC. We further found that
TV-miR-34a interference significantly inhibited
expressions of C22ORF28 and CD44 rather than
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LIN28A (Figure 6C). Taken together, we conclude that
C22ORF28 was the direct and functional target of
TV-miR-34a in long-term-cultured BCSC.

C22ORF28 mediates the inhibition effect of
TV-miR-34a on tumor-initiating properties in
long-term-cultured BCSC
We further explored the role of C22ORF28 in the
effect of TV-miR-34a on BCSC. Regulators of
C22ORF28 were preliminarily established. We found
that
addition
of
exogenous
C22ORF28
(C22ORF28-Ad)
up-regulated
expressions
of
C22ORF28 and CD44; conversely, knockdown of
C22ORF28 (C22ORF28-KD) down-regulated these
expressions in BCSC (Figure 6D). Interestingly,
C22ORF28-Ad
increased
the
proportion
of
CD44+CD24- in BCSC; while C22ORF28-KD decreased
their population (Figure 6E). Similarly, C22ORF28-KD
inhibited the clonogenicity ability of XM322 within
soft agarose; while C22ORF28-Ad promoted this
ability (Figure 6F). Furthermore, clonal pair-cell assay
was performed to evaluate the suppressive effect of
C22ORF28-KD on XM607. Encouragingly, we
indicated that C22ORF28-KD and CD44 were
mutually exclusive of each other more often than they
were co-expressed (Figure 6G). Collectively, these
processes in vitro demonstrate that knockout of
C22ORF28 could dramatically eliminate the
tumor-initiating properties of long-term-cultured
BCSC.
With a goal of evaluating the effect of C22ORF28
on the tumor-initiating biological properties of
long-term-cultured BCSC, we generated GFP-labeled
MDA-MB-231.SC (Supplementary figure S4). In
comparison with the effect on day 0, day 1 and day 3,
TV-miR-34a
treatment
significantly
inhibited
mammosphere formation of MDA-MB-231.SC on day
5; while this effect was reversed by co-transfection of
C22ORF28-3'-UTR rather than C22ORF28-3'-UTR-mut
(Figure 7A and Figure 7B). These differences were
further reflected by differences in GFP intensity.
Compared with treatment of both Ctrl and
TV-miR-Ctrl, TV-miR-34a significantly reduced the
fluorescence intensity of BCSC to a similar extent in a
time-dependent manner. Moreover, co-transfection of
C22ORF28-3'-UTR could counteract the growth
suppression mediated by TV-miR-34a in BCSC,
whereas a mutation in the C22ORF28-3'-UTR binding
sites of miR-34a did not have this effect (Figure 7A
and Figure 7C). As presented in Figure 7D,
C22ORF28-3'-UTR plasmid inhibited the eradication
effect of TV-miR-34a on GFP-labeled BCSC; hence,
C22ORF28-3'-UTR-mut plasmid conserved GFP
expression during TV-miR-34a intervention. This
result lent further credence to the notion that
http://www.thno.org
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TV-miR-34a targeted C22ORF28 directly and
functionally in long-term-cultured BCSC. In a word,
by targeting to C22ORF28 directly, TV-miR-34a
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attenuated the tumor-initiating
long-term-cultured BCSC.

properties

of

Figure 3. TV-miR-34a induces high throughput of miR-34a expression in BCSC. (A) Expression of hTERT was rarely detectable in both HME cells; while hTERT was highly
expressed in all BC and BCSC. (B) Telomerase activities in HME cells were lower than BCs and BCSC. NS: not significant. (C) Representative images of isolated single cell (upper panel) and
pair cells (low panel) expressing GFP-labeled TV-miR-34a in XM322. Scale bar, 5 µm (D) Telomerase activities among HME, BC and BCSC did not alter significantly following their
corresponding transfection with Ctrl, TV-miR-Ctrl or TV-miR-34a, respectively. Scale bar, 5 µm.(E) qRT-PCR analysis demonstrated that TV-miR-34a plasmid significantly up-regulated
miR-34a expression comparing with either TV-miR-Ctrl or Ctrl in both BCs and BCSC. (F) MTT assays of cell viabilities showed that TV-miR-34a decreased the cell viabilities in both BCSC
(MDA-MB-468, SK-BR-3, MDA-MB-231, MCF-7, parental cells of XM322 and XM607) and BCs (MDA-MB-231.SC, MCF-7.SC, XM322 and XM607); whereas, cell viabilities of HME (MCF-12A
and 184A1) were not found to be significantly different. The inhibitory effect of TV-miR-34a nanopartiple on cell viabilities of BCSC was stronger than their corresponding parental breast
cancer cells. *p<0.05, **p<0.01, ***p<0.001
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Figure 4. TV-miR-34a inhibits tumor-initiating properties of long-term-cultured BCSC in vitro. (A) Mammospheres of XM607 initiated adherence and
differentiation following TV-miR-34a interference. Scale bar, 100 µm. (B) Representative images (left panel) and statistical results (right panel) of TV-miR-34a robustly
and persistently decreasing the population of CD44+CD24- XM607; while miR-34a influence remained transient and reversible. (C) Representative images (left panel;
scale bar, 100 µm) and statistical result (right panel) of clonogenesis abilities of MCF-7.SC down-regulated by TV-miR-34a. ***p<0.001.
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Figure 5. TV-miR-34a suppresses proliferation effectively and safely in vivo. (A) TV-miR-34a inhibited the growth of luciferase-labeled XM322 bearing tumors in a
dose-dependent manner. The optimum dose is 10 µg qod. (B) TV-miR-34a plasmid significantly suppressed fluorescence intensity of XM322 (upper left: representative images).
(C) Kaplan-Meier survival analyses of TV-miR-34a prolonging mice survival in orthotopic xenograft models. (D) Body weights in all participant nude mice showed no significant
change. (E) Side effects of TV-miR-34a treatment on serum ALT (left panel) and AST (right panel). (F) Side effects of TV-miR-34a treatment on serum BUN (left panel) and Cr
(right panel). Each experiment was repeated more than three times. (G) In comparison with both groups of Ctrl and TV-miR-Ctrl, secretion levels of TNF-α (left panel), IL-6
(middle panel) and IFN-γ (right panel) in the TV-miR-34a treatment group were significantly increased from day 0 to day 10. Each experiment was repeated more than three
times. *p<0.05, **p<0.01, ***p<0.001.
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Figure 6. TV-miR-34a plays an inhibitory effect on tumor-initiating properties of long-term-cultured BCSC via directly targeting C22ORF28. (A) Schematic
diagram of Luc-C22ORF28-3'UTR and mutation of Luc-C22ORF28-3'UTR (Luc-C22ORF28-3'UTR-mut) for presence of miR-34a conversed binding sites. (B) Mutating the
predicted miR-34a binding sites within the Luc-C22ORF28-3'UTR luciferase reporter significantly abolished TV-miR-34a-dependent repression. (C) LIN28A is rarely detected in
BCSC. Both C22ORF28 and CD44, rather than LIN28A, were the inhibitory targets of TV-miR-34a treatment. (D) Constructions of C22ORF28-Ad and C22ORF28-KD can
effectively up-regulate and down-regulate expressions of C22ORF28 and CD44 in BCSC, respectively. (E) C22ORF28-Ad increased percentage of CD44+CD24- subpopulation
cells in BCSC, whereas C22ORF28-KD decreased these subpopulation cells. (F) Representative images (left panel) and statistical results (right panel) of C22ORF28-Ad
promoting sphere-formation ability within soft agarose of XM322, but C22ORF28-KD eliminating this ability. Scale bar, 100 µm. (G) Representative images (left panel) and
statistical result (right panel) of TV-miR-34a suppressing CD44 expression measured by clonal pair-cell analyses in XM607. Scale bar, 10 µm; C.E.: co-expressed; M.E.: mutually
exclusive. Each experiment was repeated at least three times. *p<0.05, **p<0.01, ***p<0.001.
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Figure 7. Evaluation of the inhibitory effect of C22ORF28 intervene on long-term-cultured BCSC during TV-miR-34a treatment. (A)
Representative images of mammosphere formation and fluorescence expression of GFP-labeled BCSC following transduction with Ctrl, TV-miR-Ctrl, TV-miR-34a,
co-transfection of TV-miR-34a plus C22ORF28-3'-UTR, as well as co-transfection of TV-miR-34a plus C22ORF28-3'-UTR-mut, respectively (L.L.: lamp light; E.L.:
exciting light). Scale bar, 100 µm. (B) Statistical results of differences in mammosphere formation. (C) Statistical results of fluorescence intensity. Each experiment was
repeated at least in triplicate. (D) Schematic diagram of C22ORF28 mediating TV-miR-34a treatment in GFP-labeled long-term-cultured BCSC. **p<0.01, ***p<0.001.
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TV-miR-34a synergizes with docetaxel for
inhibition of BCSC
In current clinical practice, the chemotherapeutic
taxanes, represented by docetaxel and paclitaxel, are
standard therapy for patients with invasive breast
cancer. In this study, we examined whether the
combination of TV-miR-34a and docetaxel may
enhance the therapeutic effect on BCSC. Limitedly,
docetaxel alone exerted no effect against
MDA-MB-231.SC (Figure 8A and Figure 8B).
However, we found that TV-miR-34a effectively
sensitized GFP-labeled MDA-MB-231.SC to docetaxel.
Docetaxel played a rare role in eradicating
MDA-MB-231.SC: the inhibition effect of TV-miR-34a
plus docetaxel on MDA-MB-231.SC was superior than
that of TV-miR-34a alone (Figure 8A and Figure 8B).
Similarly, docetaxel alone did not significantly affect
cell viability of XM322; while XM322 with
TV-miR-34a treatment showed a significant decrease
in cell viability. In particular, combination treatment
of TV-miR-34a plus docetaxel significantly decreased
cell viability in XM322 more than single treatment
alone using TV-miR-34a (Figure 8C). In line with these
above-mentioned results, we found that TV-miR-34a
alone significantly inhibited expressions of CD44 and
C22ORF28 compared with either the vector or
docetaxel treatment alone (Figure 8D). Further, the
combined usage of TV-miR-34a plus docetaxel
demonstrated even better inhibitory efficacy than
single-agent application of TV-miR-34a plasmid
(Figure 8D). Here we also found that LIN28A
expression was rarely detectable in all four BCSC lines
(Figure 8D). From the results of our previous
investigations, TV-miR-34a plasmid significantly
depressed the tumor-initiating properties of BCSC,
thereby transforming their stem-like properties to
non-stemness, along with inhibiting cell proliferation
of BCSC (Figure 8E). These results suggested that the
enhanced eradication effect induced by synergy of
TV-miR-34a and docetaxel may contribute to their
synergistic effects on the cell fate of BCSC, owing to
the transformation of CD44 positive BCSC to
non-stem-like tumor cells (Figure 8E).

C22ORF28 is frequently up-regulated in breast
tumor tissues, and positive expression is
correlated with an unfavorable prognosis.
Given the striking effect of C22ORF28 on
TV-miR-34a treatment in long-term-cultured BCSC,
we then questioned whether there was an association
between C22ORF28 expression and clinical prognosis
in patients with breast cancer. Here we evaluated
C22ORF28 expression and other clinicopathological
data from a previously reported study [3].
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Representative slides of breast cancer tissues and
corresponding adjacent healthy breast tissues are
shown in Figure 9A and 9B. Expressions of C22ORF28
were assessed by immunohistochemistry. We found
that expression of C22ORF28 was conversely related
to miR-34a level in breast cancer tissues
(Supplementary table S6). These results were
consistent with the response of miR-34a repressing
C22ORF28 in BCSC. In addition, C22ORF28 positive
probability in HBT was lower than that in patients
with stage I-II, which was less than that in stage III
(Supplementary table S6). To confirm these results of
TMA and IHC, we further evaluated four cases of
breast cancer tissues. Compared with HBT by
Western blotting, the tumor tissues had a significantly
higher expression of C22ORF28 (Figure 9C). Further
Kaplan-Meier survival analyses showed that breast
cancer patients with C22ORF28 positive expression
had shorter disease-free survival (DFS) and overall
survival (OS) than those patients with negative
expression (Figure 9D). Moreover, we found a more
favorable DFS and OS in the group that had high
expression of miR-34a than in the group with low
expression of miR-34a (Figure 9E). Therefore,
up-regulation of C22ORF28 was common in patients
with breast cancer, and C22ORF28 positive expression
was associated with a more unfavorable patient
prognosis.

Discussion
In this study, we have successfully generated
four long-term-cultured BCSC that presented
prolonged maintenance over 20 serial passages, while
retaining their tumor-initiating properties. Analyses
of microarray and qRT-PCR showed that miR-34a is
the most pronounced microRNA for further BCSC
investigation. We established hTERT promoter-driven
VISA delivery of miR-34a plasmid, which can induce
high throughput of miR-34a expression in BCSC.
TV-miR-34a significantly inhibited tumor-initiating
properties of the long-term-cultured BCSC in vitro,
along with suppressing the proliferation of BCSC in
vivo in an efficient and well-tolerated manner. Further
mechanistic studies revealed that TV-miR-34a
attenuates the tumor-initiating properties of
long-term-cultured BCSC via targeting to C22ORF28
directly.
Furthermore,
TV-miR-34a
plasmid
synergizes with docetaxel for eradicating BCSC. In
addition, investigation of clinical implication showed
that miR-34 and C22ORF28 have a negative
correlation in breast tumor tissues. Also, positive
expression of C22ORF28 is associated with an
unfavorable prognosis.
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Figure 8. TV-miR-34a has synergistic effects with docetaxel in eradication of BCSC. (A) MDA-MB-231.SC was observed with lamp light (L.L., left panel)
or exciting light (E.L., right panel) to detect the depression effects. Scale bar, 100 µm. (B) Statistical results of differences in fluorescence expressions among groups
of Ctrl, TV-miR-34a, and presence or absence of docetaxel 5 days following TV-miR-34a transduction. (C) MTT assay. (D) Docetaxel alone did not significantly alter
expressions of CD44 and C22ORF28 in BCSC, compared to untreated cells. Combined application of TV-miR-34a plus docetaxel on BCSC for 48 h significantly
decreased expressions of CD44 and C22ORF28 compared with TV-miR-34a alone. Cell line-derived (upper panel); tumor tissue-derived BCSC (low panel). (E)
Schematic Diagram. All data corresponds to the mean ± SD of three independent experiments.. *p<0.05, **p<0.01, ***p<0.001.

http://www.thno.org

Theranostics 2017, Vol. 7, Issue 19

4820

Figure 9. C22ORF28 is frequently up-regulated in breast tumor tissues, and C22ORF28 positive expression is correlated with a poor prognosis.
(A) Representative cases of breast cancer tissues immunostained with positive C22ORF28 (upper panel) and negative C22ORF28 (low panel). Scale bar, 100 µm. (B)
Representative cases of adjacent healthy breast tissues immunostained with positive C22ORF28 (upper panel) and negative C22ORF28 (low panel). Scale bar, 100 µm.
(C) Tumor tissues had a significantly higher expression of C22ORF28 than their adjacent healthy breast tissues (HBT). (D) Kaplan-Meier survival curves of
disease-free survival (left panel) and overall survival (right panel) for C22ORF28 status in surgically resected breast cancer. (E) Kaplan-Meier survival curves of
disease-free survival (left panel) and overall survival (right panel) for miR-34a status in surgically resected breast cancer. **p<0.01, ***p<0.001.
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In term of BCSC generation, we found that the
success rate for isolation of cell line-derived BCSC
purified by MACS is higher than that for isolation of
tumor tissue-derived BCSC purified by FACS.
However, this result did not denote that MACS is
always better than FACS in isolation of CSCs.
Separating the cells based on their own cellular
physical or biochemical properties, FACS and MACS
have been developed into the most widely used
techniques for cell sorting [29]. FACS method vibrates
and analyzes each cell individually [30], therefore it
may not be fit for maintenance of CSCs. However, the
tumor tissue-derived CSCs were derived from the
primary cells of human cancer tissues. In this case,
FACS is efficient enough to exclude the extracellular
matrix and the cells without stem-like properties.
Alternatively, the MACS approach is beneficial due to
its simplicity and robustness, not requiring
sophisticated fluid handling [29]. So, we speculate
that development of primary cell lines from tumor
tissues will bring about a great advance in isolation of
tumor tissue-derived CSCs. Multiple CSCs have been
isolated and identified in recent decades [31].
However, long-term-cultured CSCs are rarely
claimed. Here, we report four BCSC lineages that
have been cultured for more than 20 serial passages
and more than 3 years. We have to emphasize that
application of proper culture medium, avoiding fungi
infection and reducing unnecessary intense shock are
crucial for long-term maintenance of BCSC, whether
derived from tumor tissues or cell lines [3]. So, the
feature of inertia within CSCs may reveal that they
prefer a “quiet microenvironment” rather than
dynamic conditions.
The hypometabolism status of CSCs demands a
highly specific and efficient amplification system to
deliver anti-tumor molecules to eradicate them. VISA
system is a non-viral system, which contains two basic
elements: the two-step transcriptional amplification
system (GAL4-VP2) and the WPRE sequence [13, 22].
WPRE plays a role in stabilizing 3'UTR of microRNA
and enhancing the half-life of RNA transcripts. In
addition, GAL4-VP2 combines and activates a
therapeutic molecule. It is stated that the active
human telomerase enzyme is mainly composed of
hTERT, human telomerase RNA (hTR), and dyskerin.
In this study, we found that both hTERT expression
and telomerase activity in HME cells was significantly
inferior to either BC or BCSC. We further found that
hTERT promoter within TV-miR-34a can direct
preferential transgene expression in cancer cells and
BCSC rather than HME. Our results were consistent
with the findings of Cao et al. for HME cells [32]. They
interpreted that mRNA and protein expression of
hTERT could be up-regulated in expressing
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exogenous hTERT amplified HME, but hTR limits
telomerase activity and telomere maintenance in the
context of hTERT amplification. This explanation
indicated that TV-miR-34a drives the expression of
miR-34a selectively in BCSC and CS, but does not
drive its expression in HME.
As illustrated in Figure 10, TV-miR-34a
selectively controls the expression of miR-34a in BCSC
in five steps: (1) The hTERT promoter drives
expression of the GAL4-VP2 (two copies of VP16)
fusion protein specifically in BCSC, rather than in
adult stem cells; (2) the activator GAL4-VP2 is
expressed; (3) GAL4-VP2 discerns the promoter
G5E4T, due to G5E4T containing five GAL4 sites
positioned upstream of the adenovirus E4 TATA box;
(4) G5E4T induces the expression of the miR-34a
shRNA transcripts, and then generates miR-34a; (5)
the mature miR-34a are incorporated into the
RNA-induced silencing complex (RISC), which
induces downregulation of C22ORF28 leading to
eradication of BCSC. In untransformed human
tissues, most somatic cells lack telomerase activity,
while somatic stem and progenitor cells express low
levels of telomerase [33]. Of note, telomeres can form
G-quadruplex structures (G4) in adult stem cells.
Structures of G4 are highly stable and are difficult to
resolve during replication, which can cause
replication fork stalling (Figure 10) [33]. Additionally,
chromosomal instability coming from replication
stress can be ruled out by efficient checkpoints, which
ensures the elimination of damaged stem cells and
prevents stem cell-derived tumorigenesis [33]. It is
well known that miR-34a has been identified as a
tumor suppressor by several researches. It has been
elucidated that p53 checkpoints and the p53-miR-34
network can perform the second line of defense for
avoiding abnormal proliferation in adult stem cells
[33]. Therefore, the hTERT promoter has much less
influence on adult stem cells, resulting in very limited
target gene expression and therefore cell survival.
Similarly, recent studies in human embryonic stem
cells showed that increased TERT expression is not
functionally associated with an increase in active
telomerase, as hTR, but not TERT, is limiting [34].
Collectively, TV-miR-34a plasmid has the appropriate
construction to eradicate BCSC via an efficient and
safe approach. In the present study, in order to
provide guidance for this novel therapeutic avenue,
we have specifically analyzed the gene sequences and
schematic structure of TV-miR-34a in detail.
CSCs hold the tumor-initiating properties of
self-renewal, proliferation, specific marker and
differentiation [4, 35]. Interferences with adherence
and differentiation are the critical directions for
elimination of these progenitor cells. The therapeutic
http://www.thno.org
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approach with TV-miR-34a plasmid shows us the
“dual steps” to eradicate BCSC. On the first step,
findings regarding CD44+ CD24-/low differences, clonal
pair-cell analyses and synergistic effects of docetaxel
BCSC
are
confirm
that
CD44+ CD24-/low
asymmetrically divided into CD44 negative
heterogeneous lineages of breast cancer cells [3].
TV-miR-34a might restrict the acquisition of
expanded cell fate potential in pluripotent stem cells
through overexpression of miR-34a [5]. On the second
step, as our previous study described, TV-miR-34a
suppresses proliferation and invasion of breast cancer
cells [22]. Therefore, miR-34a overexpressed by
hTERT promoter-driven VISA plasmid can effectively
eradicate BCSC.
In the current research, we indicated that the
non-viral TV-miR-34a nanoparticle showed great
therapeutic efficacy in orthotopic xenograft models
with a high degree of safety. TV-miR-34a treatment
had no significant side effects on functions of liver
and kidney in the participant mice. No lethal
inflammatory responses were observed throughout
the study. Here, we review plausible explanations for
the increase of proinflammatory cytokines. First of all,
this is essential for the nanomaterial to play a
potential antitumor role in tumor-bearing mice [27].
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Of note, the immune response is also influenced by
the animal model. Kim and colleagues found that
various proinflammatory cytokine levels are much
higher in nude mice than wild-type mice after
treatment [36]. So, the involved nude mice are more
likely to produce a cytokine surge than wild-type
mice.
In
sum,
TV-miR-34a
treatment
for
tumor-bearing mice is well-tolerated.
There is increasing evidence that hypoxic
microenvironment promotes renewal, differentiation,
angiogenesis and accumulation of CSCs in tumor
tissues. The hypoxia-inducible factors (HIFs) family,
including HIF-1α, HIF-2α and HIF-3α, orchestrate
signaling events regulating cell survival, proliferation
and differentiation, angiogenesis, metabolism,
invasion and metastasis of cancer cells, and is
mediated prominently by HIF-1α and HIF-2α [37].
More recently, Li and colleagues found that miR-34a
is directly repressed by HIF-1α under hypoxic
conditions,
and
ectopic
miR-34a
prevents
hypoxia-induced invasion and migration in hypoxic
cancer cells [38]. Therefore, it is conceivable that
miR-34a restored by TV-miR-34a may have
therapeutic potential for hypoxia-driven formation of
invasion and metastasis in tumor tissues.

Figure 10. Schematic Diagram of the TV-miR-34a System. (A) The hTERT promoter drives expression of the GAL4-VP2 fusion protein selectively in BCSC,
but not in adult stem cells (B) GAL4-VP2 is expressed; (C) GAL4-VP2 discerns the promoter G5E4T; (D) G5E4T promotes the expression of the miR-34a protein;
(E) the mature miR-34a are incorporated into RISC, which inhibits C22ORF28 expression leading to eradication of BCSC. (F) Telomeres (mainly composed by
hTERT) form G-quadruplex structures (G4), which along with G4 can cause replication fork stalling.
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C22ORF28 is highly homologous to HSPC117
(hematopoietic stem/progenitor cell 117) in humans,
also previously known as focal adhesion associated
protein (FAAP) in mice, and RTCB (RNA 2', 3'-cyclic
phosphate and 5'-OH ligase) in prokaryotes. The high
degree of conservation of C22ORF28/RTCB proteins
from E. coli to human is suggestive of shared
important roles for this protein family in organisms
[39]. FAAP facilitates vinculin-paxillin association,
decreases interaction of paxillin-focal adhesion kinase
and reduces the phosphorylation of extracellular
signal-regulated kinase in murine [40]. In the research
of moving cells, Carmen et al. found that HSPC117
might be involved in initiation of cell spreading by
virtue of cell adhesion [41]. Recent investigations
indicated that HSPC117 mediates tRNA [39, 42] and
mRNA [25, 43] splicing. Herein, for the first time to
our knowledge, we found that C22ORF28 maintains
properties of self-renewal, proliferation, tumor
formation, CD44+CD24- subpopulation and CD44
expression in BCSC. In summary, we indicated that
TV-miR-34a promotes adherence and differentiation
in long-term maintenance of BCSC via targeting to
C22ORF28.
In conclusion, we generated long-term
maintenance of BCSC, either from clinical samples or
cell lines. We established the non-viral TV-miR-34a
plasmid, which could eradicate long-term-cultured
BCSC in a safe and efficient approach both in vitro and
in vivo. The combination of TV-miR-34a and docetaxel
enhanced the therapeutic effect on BCSC. Mechanistic
studies further indicated that TV-miR-34a suppresses
tumor-initiating properties, promotes adherence and
boosts differentiation in long-term maintenance of
BCSC through targeting C22ORF28 directly. Thus, we
developed the non-viral TV-miR-34a plasmid, which
has great potential for clinical application in breast
cancer therapies targeting to BCSC.

polyvinylidene difluoride; qod: quaque omni die;
RISC: RNA-induced silencing complex; SD: standard
deviation; TMA: tissue microarray construction;
TV-miR-34a: hTERT promoter-driven VISA delivery
of miR-34a; TV-miR-Ctrl: hTERT promoter-driven
VISA nanoparticle delivery of control; VISA:
VP16-GAL4-WPRE integrated systemic amplifier.
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mammary epithelial cells; HSPC117: hematopoietic
stem/progenitor cell 117; hTR: human telomerase
RNA; HIFs: hypoxia-inducible factors; IHC:
immunohistochemistry; MACS: magnetic-activated
cell
sorting;
OS:
overall
survival;
PVDF:
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